TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29328643

Group type: EXPERIMENTAL
Intervention: Spontaneous abortion group (group S)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Missed abortion group (group M)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (group N)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Spontaneous abortion group (group S) and Control group (group N)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Missed abortion group (group M) and Control group (group N)
Number of subjects: 120
Study: 25019381

Group type: EXPERIMENTAL
Intervention: Connecting with a stranger
Number of subjects: 0

Group type: COMPARATOR
Intervention: Disconnected (not connecting with a stranger)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal commuting (no specific instructions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Talking to a participant in a laboratory waiting room
Number of subjects: 0
Study: 22508148

Group type: EXPERIMENTAL
Intervention: Esomeprazole alone (40 mg per day)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Esomeprazole plus aspirin (40 mg per day + 100 mg per day)
Number of subjects: 178
Study: 20570363

Group type: EXPERIMENTAL
Intervention: Initial trabeculectomy in the study eye
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (untreated fellow eye)
Number of subjects: 300
Study: 18666235

Group type: COMPARATOR
Intervention: Endoscopic variceal ligation (EVL)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Nadolol plus isosorbide‐5‐mononitrate (N+I)
Number of subjects: 121
Study: 15805317

Group type: EXPERIMENTAL
Intervention: Oxycodone (5 mg orally) with acetaminophen
Number of subjects: 73

Group type: COMPARATOR
Intervention: Hydrocodone (5 mg orally) with acetaminophen
Number of subjects: 73
Study: 12839688

Group type: EXPERIMENTAL
Intervention: Jejunal interposition esophagojejunostomy (Group D)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Roux-en-y esophagojejunostomy (Group A)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: P pouch with Roux-en-y esophagojejunostomy (Group B)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Hunt-Lawrence esophagojejunostomy (Group C)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (12 healthy persons)
Number of subjects: 120
Study: 10601173

Group type: EXPERIMENTAL
Intervention: Indomethacin (150 mg/day for 48 hours)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole blood method
Number of subjects: 10
Study: 7588349

Group type: EXPERIMENTAL
Intervention: Combined therapy (N-butyl-2-cyanoacrylate and ethanolamine oleate)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sclerosis group (ethanolamine oleate)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Sclerosis group
Number of subjects: 114
Study: 1952471

Group type: EXPERIMENTAL
Intervention: Cefoperazone (3 g every 12 hours) plus piperacillin (75 mg/kg every 6 hours)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 g every 8 hours) plus piperacillin (75 mg/kg every 6 hours)
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Imipenem alone (1.0 g or 0.5 g every 6 hours)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Imipenem (4 g/d)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Cefoperazone plus piperacillin
Number of subjects: 429

Group type: COMPARATOR
Intervention: Ceftazidime plus piperacillin
Number of subjects: 429

Group type: COMPARATOR
Intervention: Imipenem (2 g/d)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Double beta-lactam therapy
Number of subjects: 429

Group type: COMPARATOR
Intervention: Imipenem
Number of subjects: 429
Study: 7191790

Group type: EXPERIMENTAL
Intervention: 2 g epicillin plus 1 g probenecid
Number of subjects: 260

Group type: COMPARATOR
Intervention: 2 g epicillin alone
Number of subjects: 260

Group type: COMPARATOR
Intervention: 1 g epicillin, 1 g cephradine plus 1 g probenecid
Number of subjects: 260

Group type: COMPARATOR
Intervention: 1 g epicillin and 1 g cephradine
Number of subjects: 260
Study: 30772993

Group type: EXPERIMENTAL
Intervention: Deproteinized calf blood extract eye drops (DCBE group)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Control group (anti-inflammatory drugs only)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Carboxymethylcellulose sodium eye drops (CMC group)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Recombinant human epidermal growth factor eye drops (rEGF group)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 114
Study: 25874620

Group type: EXPERIMENTAL
Intervention: ACEI/ARB
Number of subjects: 3276
Study: 23141817

Group type: COMPARATOR
Intervention: Liraglutide (1.8 mg once daily)
Number of subjects: 912

Group type: EXPERIMENTAL
Intervention: Exenatide (2 mg once weekly)
Number of subjects: 912
Study: 22002979

Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DP)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Chloroquine (CQ)
Number of subjects: 500
Study: 19083426

Group type: EXPERIMENTAL
Intervention: Pycnogenol (125 mg daily)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 48
Study: 16412552

Group type: EXPERIMENTAL
Intervention: 50mg prednisolone intravenously twice a day
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 14580743

Group type: EXPERIMENTAL
Intervention: Compression-only telephone CPR
Number of subjects: 59

Group type: COMPARATOR
Intervention: Standard telephone CPR instructions
Number of subjects: 59
Study: 11052521

Group type: EXPERIMENTAL
Intervention: Inulin supplementation (24 g daily for three weeks)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inulin supplementation
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Inulin treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (after wash-out period)
Number of subjects: 20
Study: 8774268

Group type: EXPERIMENTAL
Intervention: Vitamin E (280 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo (hydrogenated coconut oil)
Number of subjects: 100
Study: 1290314

Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg daily from the third postoperative day, increasing to 20 mg daily after 1 week for 11 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 6727564

Group type: EXPERIMENTAL
Intervention: BW 245C 150 micrograms
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BW 245C 50 micrograms
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BW 245C 50 and 150 micrograms
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: BW 245C
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31712086

Group type: EXPERIMENTAL
Intervention: Active tACS (10 Hz, 1 mA)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Active tACS (20 Hz, 1 mA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 30
Study: 30340524

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided selective nerve block of the median, ulnar, and medial antebrachial cutaneous nerves at the upper‐median 1/3 of the arm, and a block of the radial and musculocutaneous nerves at the low‐median 1/3 of the arm.
Number of subjects: 24

Group type: COMPARATOR
Intervention: Ultrasound-guided axillary brachial plexus blocks.
Number of subjects: 24
Study: 28431122

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral and mindfulness‐based group sleep intervention (n = 63)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Active control 'study skills' intervention (n = 60)
Number of subjects: 123
Study: 26548675

Group type: EXPERIMENTAL
Intervention: Osteoporosis education program (six-weekly education sessions)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 130
Study: 24270950

Group type: EXPERIMENTAL
Intervention: Intensive guidance by a healthcare team on a protocol for diabetes care (n=95)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard care (n=87)
Number of subjects: 182
Study: 22032743

Group type: EXPERIMENTAL
Intervention: Bilateral anodal dorsolateral prefrontal cortex (DLPFC) stimulation (n = 8)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Bilateral cathodal superior temporal gyrus (STG) stimulation (n = 5)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 12
Study: 18164304

Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 600

Group type: COMPARATOR
Intervention: Ergometrine
Number of subjects: 600
Study: 16582128

Group type: EXPERIMENTAL
Intervention: l-arginine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 14514973

Group type: EXPERIMENTAL
Intervention: Paclitaxel 175 mg/m2 and carboplatin AUC = 6 with amifostine 910 mg/m2 (group B)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Chemotherapy alone (group A)
Number of subjects: 38
Study: 10730613

Group type: EXPERIMENTAL
Intervention: Electrical cardioversion (protocol: 200, 300, 360 J)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Pharmacological cardioversion (quinidine)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Electrical cardioversion
Number of subjects: 19

Group type: COMPARATOR
Intervention: Pharmacological cardioversion
Number of subjects: 19
Study: 8956954

Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 40

Group type: COMPARATOR
Intervention: Albumin
Number of subjects: 40
Study: 1316074

Group type: EXPERIMENTAL
Intervention: Lomefloxacin (400 mg orally once daily for 7-10 days)
Number of subjects: 254

Group type: COMPARATOR
Intervention: TMP/SMX (160 mg/800 mg orally twice daily for 7-10 days)
Number of subjects: 254
Study: 2860441

Group type: EXPERIMENTAL
Intervention: Weight reduction
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Metoprolol (200 mg daily)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study: 29193881

Group type: COMPARATOR
Intervention: Knowledge of Disease Management‐Cystic Fibrosis measure (KDM‐CF‐P)
Number of subjects: 196

Group type: COMPARATOR
Intervention: KDM‐CF‐P (19 items)
Number of subjects: 196

Group type: COMPARATOR
Intervention: KDM‐CF‐P
Number of subjects: 196
Study: 26045250

Group type: EXPERIMENTAL
Intervention: Denicotinized cigarettes (DNCs) used ad libitum over 2 weeks in addition to standard treatment (ST)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard treatment (ST) alone
Number of subjects: 200
Study: 24531244

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 52
Study: 21967300

Group type: EXPERIMENTAL
Intervention: Computer games operated by leaning in a seated position, duration: 3 months, controlled using a sitting platform that detects pressure changes.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group), duration: 3 months, participants acted as their own controls.
Number of subjects: 0
Study: 20925607

Group type: EXPERIMENTAL
Intervention: Modified definition of fetal heart rate deceleration
Number of subjects: 104

Group type: COMPARATOR
Intervention: Standard definition of fetal heart rate deceleration
Number of subjects: 104
Study: 18541548

Group type: EXPERIMENTAL
Intervention: n‐3 FAs group (1.7 g DHA and 0.6 g EPA)
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 16758479

Group type: EXPERIMENTAL
Intervention: Riluzole (200 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 15
Study: 12680887

Group type: COMPARATOR
Intervention: Quazepam 20 mg after fasting overnight
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quazepam 20 mg 30 min after eating a standard meal
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Quazepam 20 mg 3 h after eating a standard meal
Number of subjects: 9
Study: 9004103

Group type: EXPERIMENTAL
Intervention: Active treatment (nitrendipine 10-40 mg/day, captopril 12.5-50 mg/day, hydrochlorothiazide 12.5-50 mg/day as necessary)
Number of subjects: 1245

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1245
Study: 1310374

Group type: EXPERIMENTAL
Intervention: High-linoleic acid (LA) diet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Low-linoleic acid (LA) diet
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fish-oil supplement (1.6 g EPA/d and 0.32 g DHA as triglycerides)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no fish-oil supplement)
Number of subjects: 30
Study: 6395815

Group type: EXPERIMENTAL
Intervention: Tinidazole 600 mg twice daily for five days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metronidazole 800 mg three times daily for five days
Number of subjects: 0
Study: 30204729

Group type: EXPERIMENTAL
Intervention: Facedown (FD) positioning for 3 days after surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: No-facedown (nFD) positioning
Number of subjects: 80
Study: 30551340

Group type: EXPERIMENTAL
Intervention: SCIT + TAU
Number of subjects: 30

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 30
Study: 26508531

Group type: EXPERIMENTAL
Intervention: FIFA 11+ Kids intervention (15-min warm-up programme, twice a week for 10 weeks)
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: FIFA 11+ Kids intervention
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard warm-up (sham treatment)
Number of subjects: 123
Study: 24581993

Group type: EXPERIMENTAL
Intervention: Interactive Simulation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Non‐interactive Simulation
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Video Tutorial
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control
Number of subjects: 56
Study: 22924354

Group type: EXPERIMENTAL
Intervention: Acacia arabica gel
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Acacia arabica powder
Number of subjects: 120

Group type: COMPARATOR
Intervention: 1% chlorhexidine gel
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 20731975

Group type: EXPERIMENTAL
Intervention: Computer-based training version of cognitive-behavioral therapy
Number of subjects: 76
Study: 17591660

Group type: EXPERIMENTAL
Intervention: Intravenous ketamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: Schizophrenia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 16249780

Group type: EXPERIMENTAL
Intervention: Kinesitherapy (KT) and orthoses (O) (O+KT group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Orthoses (O) group
Number of subjects: 48
Study: 11927475

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion at a rate of 0.1 microg x kg(‐1) x min(‐1) for 20 min
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group with normal renal function
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion in renal failure group
Number of subjects: 13

Group type: COMPARATOR
Intervention: Remifentanil infusion in control group
Number of subjects: 13
Study: 10188118

Group type: EXPERIMENTAL
Intervention: Unna cap dressing (Aquaphor gauze and Dome Paste gauze, wound care every 3 days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Standard treatment (Xeroform gauze, daily wound care)
Number of subjects: 12
Study: 8654454

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Instrumented valgus‐varus laxity tester (VVLT)
Number of subjects: 21
Study: 2138048

Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin
Number of subjects: 22
Study: 7004050

Group type: EXPERIMENTAL
Intervention: Oral PGE2 (0.5 mg initial dose, followed by 1.0 mg at hourly intervals for up to 24 hours)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Intravenous infusion of oxytocin (dose increased stepwise up to 20 mIU/min)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral PGE2 or intravenous infusion of oxytocin combined with early amniotomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oxytocin alone
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral PGE2 or intravenous infusion of oxytocin
Number of subjects: 200
Study: 30388320

Group type: EXPERIMENTAL
Intervention: Triptorelin 22.5 mg/24 week depot injections
Number of subjects: 58

Group type: COMPARATOR
Intervention: Subcapsular orchiectomy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Number of subjects: 58
Study: 28394850

Group type: EXPERIMENTAL
Intervention: Internet Group (n = 84)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Workbook Group (n = 94)
Number of subjects: 178
Study: 25586473

Group type: EXPERIMENTAL
Intervention: Avatar-based online self-management program
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (identical online program with voice only)
Number of subjects: 41
Study: 23811316

Group type: EXPERIMENTAL
Intervention: 12-week arm-cranking exercise program (3 sessions/week, moderate intensity 50%-65% HRR)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 12-week arm-cranking exercise program
Number of subjects: 17
Study: 21232631

Group type: EXPERIMENTAL
Intervention: Omega-3 group (6 g/day of fish oil for ≥1 month)
Number of subjects: 49
Study: 19133920

Group type: EXPERIMENTAL
Intervention: Desloratadine (DL) 5 mg/day (continuous)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Desloratadine (DL) PRN
Number of subjects: 106
Study: 17340895

Group type: EXPERIMENTAL
Intervention: Titanium oxide (TiO) implants
Number of subjects: 10

Group type: COMPARATOR
Intervention: Machined implants
Number of subjects: 10

Group type: COMPARATOR
Intervention: Both TiO and machined implants
Number of subjects: 10

Group type: COMPARATOR
Intervention: Machined implants in distal positions
Number of subjects: 10
Study: 15452389

Group type: EXPERIMENTAL
Intervention: Lower limb compression bandaging (pressure approximately 30 mm Hg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Unbandaged state
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Bandaged state
Number of subjects: 61
Study: 11258688

Group type: EXPERIMENTAL
Intervention: Specialty clinic asthma care (intensive medical and environmental control, education, close monitoring, 24-hour availability)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Specialty clinic asthma care
Number of subjects: 300
Study: 9926148

Group type: EXPERIMENTAL
Intervention: Exercise training (6‐min treadmill walking test and five walking sessions per day at > or = 75% of the respective treadmill walking distance)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (only treadmill walking tests on days 1, 5, and 10)
Number of subjects: 29
Study: 8056732

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI) 200 mg daily in divided doses
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Desipramine (DMI)
Number of subjects: 60
Study: 2737733

Group type: EXPERIMENTAL
Intervention: Dilevalol 200-400 mg daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Atenolol 50-100 mg daily
Number of subjects: 12
Study: 31398669

Group type: EXPERIMENTAL
Intervention: Physostigmine salicylate (0.04 mg/kg initial dose, followed by continuous infusion of 1 mg/h for up to 120 h)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride)
Number of subjects: 20
Study: 28441944

Group type: EXPERIMENTAL
Intervention: Cash transfer program (CTP) of US$40 monthly for 6 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no cash transfer)
Number of subjects: 0
Study: 26493793

Group type: EXPERIMENTAL
Intervention: carlumab 1 mg·kg(‐1)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: carlumab 5 mg·kg(‐1)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: carlumab 15 mg·kg(‐1)
Number of subjects: 126

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 126
Study: 24298731

Group type: EXPERIMENTAL
Intervention: Edoxaban (60 mg once daily) after initial heparin (5 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin (INR of 2.0-3.0) after initial heparin (5 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Edoxaban (30 mg once daily)
Number of subjects: 0
Study: 21486803

Group type: EXPERIMENTAL
Intervention: Infusion of N(G)-nitro-L-arginine methyl ester (L-NAME) for 5 min to inhibit NOS during continuous SS hypoxia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Infusion of ketorolac for 5 min to inhibit COX during continuous SS hypoxia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combined NOS and COX inhibition
Number of subjects: 20

Group type: COMPARATOR
Intervention: Infusion of ketorolac during SS hypoxia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Infusion of L-NAME during continuous SS hypoxia
Number of subjects: 20
Study: 19321206

Group type: EXPERIMENTAL
Intervention: Risperidone augmentation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo augmentation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PaRTS‐D instrument
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PaRTS‐D scores
Number of subjects: 0
Study: 16677167

Group type: EXPERIMENTAL
Intervention: Camostat mesilate 200 mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Famotidine 20 mg twice daily
Number of subjects: 0
Study: 14997744

Group type: EXPERIMENTAL
Intervention: Mammographic screening for breast cancer
Number of subjects: 0
Study: 11174691

Group type: EXPERIMENTAL
Intervention: Ankle mortise separation adjustment
Number of subjects: 30

Group type: COMPARATOR
Intervention: Detuned ultrasound treatment (placebo)
Number of subjects: 30
Study: 9413706

Group type: EXPERIMENTAL
Intervention: Metrifonate (loading/maintenance dosages 2/0.65 mg/kg/day for 2 and 10 weeks)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo (n = 120)
Number of subjects: 119
Study: 8423964

Group type: EXPERIMENTAL
Intervention: Educational brochure
Number of subjects: 125

Group type: COMPARATOR
Intervention: No brochure (Control)
Number of subjects: 125
Study: 3680568

Group type: EXPERIMENTAL
Intervention: Ciramadol 30 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ciramadol 90 mg
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study: 28834135

Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice daily
Number of subjects: 40